Pharmaceutical

Aspect wins $72.75m from Canadian government for bioprinted pipeline

Novo Nordisk-partnered Aspect develops bioprinted tissue therapeutics designed to replace or support specific biological functions.

Jul 12, 2024 - 04:00
Aspect wins $72.75m from Canadian government for bioprinted pipeline
Novo Nordisk-partnered Aspect develops bioprinted tissue therapeutics designed to replace or support specific biological functions.
Read the original article

Tags:

Previous Article

Merz wins $185m bid for bankrupt Acorda assets and increases US workforce by 50%

Next Article

After AdCom rejection, FDA rebuffs Novo Nordisk’s once-weekly insulin

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Astellas and Sangamo sign capsid deal for neurological diseases

Astellas and Sangamo sign capsid deal for neurological ...

Dec 21, 2024

BioVersys and GSK expand their partnership for TB treatment alpibectir

BioVersys and GSK expand their partnership for TB treat...

May 9, 2024

STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic

STAT+: The Ozempic panic: Why a market frenzy over new ...

Oct 18, 2023